Skip to main content
Publications
Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 2017 ACR/ARHP Annual Meeting; November 5, 2017. San Diego, CA.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, Sherif B, Williams N, Keat A. Impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-naïve patients with active ankylosing spondylitis. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Williame C, Rosillon D, Zima J, Angelo MG, Stuurman A, Vroling H, van Staa T, Boggon R, Bunge E, Pladevall-Vila M, Baril L. Risk of autoimmune diseases (AD) after human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine immunization in women aged 9 to 25 years in the United Kingdom: an observational cohort study. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue S. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 15, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(Suppl 2):AB212.